Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 51

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Leptin Receptor - Pipeline Review, H2 2018'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 9 molecules.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively.

Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Oncology and Ophthalmology which include indications Obesity, Lipodystrophy, Acquired Generalized Lipodystrophy (Lawrence Syndrome), Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome), Alzheimer's Disease, Breast Cancer, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome), Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

- The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects

- The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
Jyant Technologies Inc
NeuroNano Pharma Inc
Neurotez Inc
Novelion Therapeutics Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
Allo-Aca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
memtin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-4461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
Featured News & Press Releases
Jun 25, 2018: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Jun 01, 2018: MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Sep 15, 2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin
Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin
May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy
Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy
Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Jyant Technologies Inc, H2 2018
Pipeline by NeuroNano Pharma Inc, H2 2018
Pipeline by Neurotez Inc, H2 2018
Pipeline by Novelion Therapeutics Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by XL-protein GmbH, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Viral Conjunctivitis Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Sep-2018        Price: US 3480 Onwards        Pages: 121
    Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period. Scope of the Report: This report f......
  • Global Vitamin B-complex Ingredients Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Sep-2018        Price: US 3480 Onwards        Pages: 135
    Vitamins are organic compounds that are required by living organisms in minute quantities to maintain a normal metabolic activity. These compounds usually cannot be synthesized by the organism and have to be obtained through external sources. The term "vitamin" is a generic descriptor for a group of chemical compounds or ingredients that have similar molecular structure and have the capability to perform the required vitamin-activity. These chemical compounds or vitamin ingredients are often cal......
  • Global Secondary Oral Hygiene Products Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Sep-2018        Price: US 3480 Onwards        Pages: 137
    Secondary oral hygiene can be described as the usage of products for the protection of gums from periodontal diseases. It includes mouthwashes, dental flosses, mouth fresheners, teeth whitening products, and mouth dentures. Scope of the Report: This report focuses on the Secondary Oral Hygiene Products in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacture......
  • Global Vaginal Odor Control Product Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Sep-2018        Price: US 3480 Onwards        Pages: 101
    One of the most commonly occurring and least talked about feminine concerns is vaginal odor. Every woman has a unique scent that fluctuates during her menstrual cycle and may change depending upon hormone levels. The scent originates from vaginal secretions and can vary throughout the month. Scope of the Report: This report focuses on the Vaginal Odor Control Product in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East a......
  • Global Sexual Wellness Products Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 24-Sep-2018        Price: US 3480 Onwards        Pages: 136
    Sexual wellness refers to the physical, mental, and sexual well-being of people. Products such as erotic lingerie, condoms and contraceptives, personal lubricants, sex toys, and others such as testing cards and pregnancy testing kits, sexual enhancement supplements, sex games, and vaginal sexual wellness products, which enhance safety and pleasure of sexual experiences, are considered sexual wellness products. Scope of the Report: This report focuses on the Sexual Wellness ......
  • Global Etoposide Market Insights, Forecast to 2025
    Published: 24-Sep-2018        Price: US 3900 Onwards        Pages: 118
    This report studies the global market size of Etoposide in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Etoposide in these regions. This research report categorizes the global Etoposide market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, ......
  • Global Oseltamivir Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 24-Sep-2018        Price: US 3480 Onwards        Pages: 102
    Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B (flu). Scope of the Report: This report focuses on the Oseltamivir in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Oseltamivir is expected to grow at a CAGR of roug......
  • Global Over The Counter (OTC) Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 24-Sep-2018        Price: US 3480 Onwards        Pages: 119
    Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a prescription from a healthcare professional, as opposed to prescription drugs, which may be sold only to consumers possessing a valid prescription. Scope of the Report: This report focuses on the Over The Counter (OTC) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, re......
  • Global Over the Counter (OTC) Drugs & Dietary Supplements Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 24-Sep-2018        Price: US 3480 Onwards        Pages: 136
    Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a prescription from a healthcare professional, as opposed to prescription drugs, which may be sold only to consumers possessing a valid prescription. Dietary supplements are products intended to supplement the diet. They are not drugs and, therefore, are not intended to treat, diagnose, mitigate, prevent, or cure diseases. This report analyzed both OTC drugs and dietary supplements. Scope of the Report:......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs